TRI Strategic Plan 2019 - 2021

TRI has four shareholder organisations: Queensland Health Princess Alexandra Hospital (PAH), Mater Medical Research Institute (MMRI), The University of Queensland (UQ) and the Queensland University of Technology (QUT). The TRI concept was funded and mandated by the Australian Government and Queensland Government with support from Atlantic Philanthropies, QUT and UQ.

OUR VISION: TRI will be a global leader in the effective translation of research and innovation into improved healthcare. 

Mission:

To promote the translation of innovative research into clinical practice, TRI provides world-class research facilities, effective clinical interfaces, links to industry and government and a workforce effective in the translational pathways. 

 

GOAL 1– PROMOTE AND INCREASE INNOVATIVE TRANSLATIONAL RESEARCH

Strategies

1. Create an environment that encourages collaboration, innovation and excellence. 

2. Work with the university Senior Managers, hospital CEOs and State Government-Directors General (Health, Science, Innovation and Manufacturing & Industry Development) to consider, and pursue, new initiatives leading to an increase, healthcare delivery and product delivery.

3. Improve on the interface between clinicians and scientists to solve important clinical questions.

4. Form strong collaborations with internationally-recognized institutions to both learn from and jointly deliver product and/or improved healthcare outcomes. In doing so, provide a means of benchmarking TRI internationally.

Outcome
Recognition, both nationally and internationally, for the successful interface of academia, medicine and industry and for translational outcomes. 

 GOAL 2 – PROVIDE WORLD CLASS FACILITIES 

Strategies

1. In collaboration with shareholder organisations, ensure that the combined internationally competitive strengths, which include but are not limited to immunotherapy, diagnostic genomics, diagnostic imaging, complex integrated surgical planning, and dermoscopy, have access to state-of-the-art human and hardware infrastructure.  

2. In collaboration with shareholder organisations, ensure that TRI has a computing capability that exploits: 
    - the advantages of the digital hospital integrating with innovative research and development programs; and ensures a
    - secure data transfer system to facilitate ease of access for TRI programs that do not yet have digital capacity.

3. Work with shareholders to maintain the leading edge facilities at TRI and in Brisbane through cost sharing where appropriate.​

Outcome
Enhancement of TRI’s competitive position nationally and internationally and attraction of world-class clinicians and researchers to TRI.

Goal 3 – Effective clinical interfaces

Strategies

1. Deliver new clinical trials capability to “partner” with internationally recognised sites and in doing so fulfill the requirements for United States FDA approved trials. 

2. Increase participation in clinical trials by all partners and stakeholders.

3. Address clinician-driven questions in a seamless manner with multidisciplinary teams that include world-leading genomics, immunology, imaging and health economic evaluations, with a patient and industry interface, to deliver product and/or improved health outcomes.

4. Provide additional support to full time clinicians supporting translational research programs, by providing research nurses, program managers and other program support.  Expand “Translational Trials” with TRI becoming a trial centre sought after by clinical and commercial enterprises nationally and internationally. 

5. Ensure that the startups in TRI have access to clinical trials capability.

Outcome
Improved healthcare by ensuring that early innovative translational research is successfully implemented into clinical practice where possible with industry interface. This will enhance the national and international standing of TRI and partners.  
 

GOAL 4 – STRENGTHEN RESEARCH LINKS TO INDUSTRY AND GOVERNMENT


Strategies

1. Promote a strong, cohesive presence by TRI, its shareholders and stakeholders, in South East Queensland. 

2. Form strong collaborations locally, nationally and internationally to deliver on State and Federal Government initiatives as well as business opportunities.

3. Provide strong support for the new programs now under development at TRI that include, but are not limited to, the role of the microbiome in health and disease; tissue engineering for complex reconstructive surgery; prevention of acute pain transitioning to chronic pain.

4. Ensure that a business and marketing capability is available to support opportunities.

5. Ensure that TRI leadership in specific translational disciplines, is documented and clearly visible to current and potential academic, commercial and government partners.

6. Work with the State Government to expand the presence of industry onsite at TRI, including startups and big industry, to strengthen the interface with industry and assist them achieve translational outcomes.

7. Make available health economic evaluations in order to generate commercial and government interest and support.

8. Engage closely with the CrossRiver Rail development.

Outcome
TRI, with its partners and stakeholders, will be well prepared to participate in national and international initiatives.

GOAL 5 – GENERATE HEALTH WORKFORCE CAPABILITY IN THE TRANSLATION OF INNOVATION

Strategies

1. Create a positive culture and environment that promotes collaboration and educates on the translational pipeline(s) used to translate a wide variety of scientific and clinical research. 

2. Train future leaders in the successful translation of innovation and in particular how to interface with industry and to think globally. 

3. Maintain and enhance the SPARQ-Ed program for inspiring primary and secondary school children to consider a career in biomedical research.

4. Embed a new Stanford Spark program at TRI to assist the new innovation programs to learn from, and work with, industry and business. In doing so train future leaders in how to translate and interface with industry. 

5. Support the TRI Science Business Inspiration Series to encourage early career researchers and clinicians. 

Outcome
The next generations educated in how best to innovate, translate and interface with industry.  Expansion of Australia’s medical technology, healthcare delivery and export industries, generating new jobs and economic growth.

vision & VAlues:

TRI’s vision is to be recognised as a global leader in effective translation of research and innovation into improved healthcare. The TRI vision is achieved through a values driven corporate culture focused on collaboration to achieve excellence.

We LIKE Collaboration

  Leadership:

Our actions will shape a healthier world

  Integrity:        

We do the right thing. Always

  Knowledge:

Through sharing, we empower innovation

  Excellence:

We strive for exceptional outcomes 

 Collaboration:

Together we’re better